TransMedics Group (TMDX) to Release Quarterly Earnings on Tuesday

TransMedics Group (NASDAQ:TMDX) is expected to be releasing its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect TransMedics Group to post earnings of $0.41 per share and revenue of $155.2790 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

TransMedics Group Trading Up 1.0%

TransMedics Group stock opened at $129.84 on Tuesday. The stock has a 50-day moving average price of $132.18 and a 200 day moving average price of $125.62. TransMedics Group has a 52 week low of $62.07 and a 52 week high of $156.00. The stock has a market cap of $4.44 billion, a PE ratio of 52.57 and a beta of 2.06. The company has a current ratio of 7.69, a quick ratio of 7.13 and a debt-to-equity ratio of 1.43.

Insider Transactions at TransMedics Group

In related news, CFO Gerardo Hernandez sold 920 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $139.62, for a total transaction of $128,450.40. Following the transaction, the chief financial officer directly owned 15,064 shares of the company’s stock, valued at approximately $2,103,235.68. The trade was a 5.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Anil P. Ranganath sold 3,000 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total transaction of $435,660.00. Following the completion of the sale, the insider directly owned 13,955 shares of the company’s stock, valued at $2,026,545.10. This trade represents a 17.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 8,920 shares of company stock valued at $1,257,310 over the last quarter. Company insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of institutional investors have recently added to or reduced their stakes in the company. Two Sigma Investments LP lifted its stake in shares of TransMedics Group by 54.2% in the third quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock worth $71,291,000 after acquiring an additional 223,409 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of TransMedics Group by 11.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock valued at $119,997,000 after purchasing an additional 113,817 shares in the last quarter. Jump Financial LLC boosted its stake in shares of TransMedics Group by 482.7% during the 3rd quarter. Jump Financial LLC now owns 127,032 shares of the company’s stock valued at $14,253,000 after buying an additional 105,232 shares during the last quarter. Man Group plc grew its position in shares of TransMedics Group by 360.8% during the third quarter. Man Group plc now owns 113,556 shares of the company’s stock worth $12,741,000 after buying an additional 88,914 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of TransMedics Group by 20.6% in the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after buying an additional 86,721 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Needham & Company LLC boosted their price objective on shares of TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Piper Sandler reiterated an “overweight” rating on shares of TransMedics Group in a report on Monday, December 22nd. Wall Street Zen upgraded TransMedics Group from a “hold” rating to a “buy” rating in a report on Saturday. Canaccord Genuity Group upped their target price on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Finally, Morgan Stanley increased their target price on TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. Six analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $144.25.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.